[
  {
    "ts": null,
    "headline": "Why Pfizer (PFE) Shares Are Sliding Today",
    "summary": "Shares of global pharmaceutical company Pfizer (NYSE:PFE) fell 2.5% in the morning session after the company cut its stake in its pandemic partner BioNTech by more than half, a move that overshadowed other company developments.",
    "url": "https://finnhub.io/api/news?id=bcaddddfea325a1da101721ba85679329feb9b348cb22b0d56b893816899c42c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763138162,
      "headline": "Why Pfizer (PFE) Shares Are Sliding Today",
      "id": 137480403,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Pfizer (NYSE:PFE) fell 2.5% in the morning session after the company cut its stake in its pandemic partner BioNTech by more than half, a move that overshadowed other company developments.",
      "url": "https://finnhub.io/api/news?id=bcaddddfea325a1da101721ba85679329feb9b348cb22b0d56b893816899c42c"
    }
  },
  {
    "ts": null,
    "headline": "Pharma ETFs in Spotlight Following Robust Q3 Earnings Results",
    "summary": "Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.",
    "url": "https://finnhub.io/api/news?id=469476e1c5e3b37cd8290dd50c679e28e3d6eb5ae8047acb8f21f3f31eca06ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763125140,
      "headline": "Pharma ETFs in Spotlight Following Robust Q3 Earnings Results",
      "id": 137480131,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.",
      "url": "https://finnhub.io/api/news?id=469476e1c5e3b37cd8290dd50c679e28e3d6eb5ae8047acb8f21f3f31eca06ee"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Cuts BioNTech Stake by More Than Half",
    "summary": "Move marks shift after years of mRNA collaboration that produced COVID-19 vaccine.",
    "url": "https://finnhub.io/api/news?id=4d2a6e251bf1653c6a7976735dd37cc12300aa2d13ff6634f350d1b996af4a5e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763120512,
      "headline": "Pfizer Cuts BioNTech Stake by More Than Half",
      "id": 137480405,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Move marks shift after years of mRNA collaboration that produced COVID-19 vaccine.",
      "url": "https://finnhub.io/api/news?id=4d2a6e251bf1653c6a7976735dd37cc12300aa2d13ff6634f350d1b996af4a5e"
    }
  },
  {
    "ts": null,
    "headline": "Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal",
    "summary": "Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.",
    "url": "https://finnhub.io/api/news?id=9ee3a50118c6b40265a7f5262ca803264af8472d394819571c2dcb0fc3faf3f5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763118360,
      "headline": "Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal",
      "id": 137480397,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.",
      "url": "https://finnhub.io/api/news?id=9ee3a50118c6b40265a7f5262ca803264af8472d394819571c2dcb0fc3faf3f5"
    }
  },
  {
    "ts": null,
    "headline": "Is that pharma influencer human or AI?",
    "summary": "Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.",
    "url": "https://finnhub.io/api/news?id=7a1bb1a8976bd6022d7a31a9151b25f306ded26ddbc5d92fcbbbfe140bb39aaa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763107200,
      "headline": "Is that pharma influencer human or AI?",
      "id": 137480221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.",
      "url": "https://finnhub.io/api/news?id=7a1bb1a8976bd6022d7a31a9151b25f306ded26ddbc5d92fcbbbfe140bb39aaa"
    }
  },
  {
    "ts": null,
    "headline": "Novo’s New Chairman Urged to Curb Risk After Metsera Drama",
    "summary": "Investors are meeting on Friday to elect Lars Rebien Sorensen to lead the supervisory board less than a week after Novo lost a bidding war with Pfizer Inc. The outcome is a foregone conclusion as the Dane, who ran the company for 16 years, also heads the Novo Nordisk Foundation, the controlling shareholder that holds 77% of Novo’s voting rights.",
    "url": "https://finnhub.io/api/news?id=1867aa0fc4be71707d05d327718175fabfcade42038e83524e166c35e772532f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763106069,
      "headline": "Novo’s New Chairman Urged to Curb Risk After Metsera Drama",
      "id": 137478327,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investors are meeting on Friday to elect Lars Rebien Sorensen to lead the supervisory board less than a week after Novo lost a bidding war with Pfizer Inc. The outcome is a foregone conclusion as the Dane, who ran the company for 16 years, also heads the Novo Nordisk Foundation, the controlling shareholder that holds 77% of Novo’s voting rights.",
      "url": "https://finnhub.io/api/news?id=1867aa0fc4be71707d05d327718175fabfcade42038e83524e166c35e772532f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's shareholders approve chaotic board overhaul as weight loss market challenges loom",
    "summary": "Novo Nordisk shareholders approved the proposals to revamp the board with 93% voting in favor. The foundation controls over 75% of votes.",
    "url": "https://finnhub.io/api/news?id=959533f8f72246a44f2593734d72d3b8506bc762a25d813d9aed8b8a7b250b61",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763092111,
      "headline": "Novo Nordisk's shareholders approve chaotic board overhaul as weight loss market challenges loom",
      "id": 137479775,
      "image": "https://image.cnbcfm.com/api/v1/image/108226063-1763122756299-gettyimages-2197227432-AFP_36X97EZ.jpeg?v=1763122810&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "Novo Nordisk shareholders approved the proposals to revamp the board with 93% voting in favor. The foundation controls over 75% of votes.",
      "url": "https://finnhub.io/api/news?id=959533f8f72246a44f2593734d72d3b8506bc762a25d813d9aed8b8a7b250b61"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Strengthens Pipeline With $10B Metsera Deal Amid Solid Q3 Results",
    "summary": "Pfizer beats Q3 estimates, raises FY guidance, acquires Metsera for obesity drugs, and offers a 7% yield. Read here for an analysis of PFE stock.",
    "url": "https://finnhub.io/api/news?id=426ac9838934eb8aaa1c2d5f16eaac08a97b127e7164c061a749b27f523cf0b4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763084780,
      "headline": "Pfizer Strengthens Pipeline With $10B Metsera Deal Amid Solid Q3 Results",
      "id": 137476760,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372778958/image_1372778958.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer beats Q3 estimates, raises FY guidance, acquires Metsera for obesity drugs, and offers a 7% yield. Read here for an analysis of PFE stock.",
      "url": "https://finnhub.io/api/news?id=426ac9838934eb8aaa1c2d5f16eaac08a97b127e7164c061a749b27f523cf0b4"
    }
  },
  {
    "ts": null,
    "headline": "Merck nears deal for flu-prevention biotech Cidara",
    "summary": "Merck is nearing a deal to buy Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu, after besting...",
    "url": "https://finnhub.io/api/news?id=3566f9475e27427ffb6e37e9cff82f995ef396a72960459d0c98bc19fa66a659",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763078863,
      "headline": "Merck nears deal for flu-prevention biotech Cidara",
      "id": 137476947,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Merck is nearing a deal to buy Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu, after besting...",
      "url": "https://finnhub.io/api/news?id=3566f9475e27427ffb6e37e9cff82f995ef396a72960459d0c98bc19fa66a659"
    }
  }
]